echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shionogi over $480 million to help develop new antifungal drug

    Shionogi over $480 million to help develop new antifungal drug

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, Shionogi and F2G announced a strategic collaboration to develop and commercialize olorofim, a novel antifungal drug for the treatment of invasive fungal infections, in Europe and As.

    Invasive aspergillosis (IA) is a potentially fatal rare disease that occurs primarily in immunocompromised patients, including those who have received cancer chemotherapy or hematopoietic stem cell transplantati.

    Olorofim (F901318) is a novel oral antifungal drug developed by F2G for the treatment of IA and other rare fungal infectio.

    ▲Olorofim molecular structure (Image source: PubChem)

    Olorofim is currently undergoing a Phase 2b open-label stu.

    Under the terms of the agreement, Shionogi will conduct clinical trials and subsequent registration and commercialization of olorofim for the treatment of IA in Europe and As.


    Shionogi & .

    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.